ArticleThe lancet. HIV2018

Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research.

Jienchi Dorward et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.